Expression of renal 11β-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function

European Journal of Endocrinology

Volumn 153, Issue 2, 2005, Pages 291-299

  Quinkler, Marcus ^a,c   Zehnder, Daniel ^b   Lepenies, Julia ^b   Petrelli, Massimiliano D ^a   Moore, Jasbir S ^a   Hughes, Susan V ^a   Cockwell, Paul ^b   Hewison, Martin ^a   Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CORTISONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROCORTISONE; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; POTASSIUM; SODIUM; TETRAHYDROCORTISOL; TETRAHYDROCORTISONE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CORRELATION FUNCTION; CREATININE CLEARANCE; DISEASE SEVERITY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYDROCORTISONE URINE LEVEL; HYPERTENSION; IMMUNOFLUORESCENCE MICROSCOPY; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MICROALBUMINURIA; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; SODIUM RETENTION; SODIUM URINE LEVEL; ADOLESCENT; ALBUMINURIA; BIOPSY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; KIDNEY FAILURE; METABOLISM; MIDDLE AGED; PATHOLOGY; URINE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; BIOPSY; CREATININE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDROCORTISONE; KIDNEY; KIDNEY FAILURE; MALE; MIDDLE AGED; RECEPTORS, MINERALOCORTICOID; RNA, MESSENGER; SODIUM; TETRAHYDROCORTISOL;

EID: 23844465211     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01954     Document Type: Article

References (50)

1. Albiston AL, Obeyesekere VR, Smith RE & Krozowski ZS. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Molecular and Cellular Endocrinology 1994 105 R11-R17.
2. Tannin GM, Agarwal AK, Monder C, New MI & White PC. The human gene for 11β-hydroxysteroid dehydrogenase: structure, tissue distribution, and chromosomal localization. Journal of Biological Chemistry 1991 266 16653-16658.
3. Stewart PM & Krozowski ZS. 11β-Hydroxysteroid dehydrogenase. Vitamins and Hormones 1999 57 249-324.
4. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE & Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987 237 268-275.
5. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER & Monder C. Localisation of 11β-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet 1988 2 986-989.
6. Funder JW, Pearce PT, Smith R & Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988 242 583-585.
7. Quinkler M, Bappal B, Draper N, Atterbury AJ, Lavery GG, Walker EA, DeSilva V, Taylor NF, Hala S, Rajendra N & Stewart PM. Molecular basis for the Apparent Mineralocorticoid Excess syndrome in the Oman population. Molecular and Cellular Endocrinology 2004 217 143-149.
8. Werder E, Zachmann M, Vollmin JA, Veyrat R & Prader A. Unusual steroid excretion in a child with low renin hypertension. Research in Steroids 1974 6 385-389.
9. New MI, Levine LS, Biglieri EG, Pareira J & Ulick S. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. Journal of Clinical Endocrinology and Metabolism 1977 44 924-933.
10. Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC, Rauh W, Rosler A, Bradlow HL & New MI. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. Journal of Clinical Endocrinology and Metabolism 1979 49 757-764.
11. Quinkler M & Stewart PM. Hypertension and the cortisol-cortisone shuttle. Journal of Clinical Endocrinology and Metabolism 2003 88 2384-2392.
12. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH & Edwards CR. Mineralocorticoid activity of liquorice: 11β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987 2 821-824.
13. Agarwal AK, Giacchetti G, Lavery G, Nikkila H, Palermo M, Ricketts M, McTernan C, Bianchi G, Manunta P, Strazzullo P, Mantero F, White PC & Stewart PM. CA-repeat polymorphism in intron 1 of HSD11B2: effects on gene expression and salt sensitivity. Hypertension 2000 36 187-194.
14. Lavery GG, McTernan CL, Bain SC, Chowdhury TA, Hewison M & Stewart PM. Association studies between the HSD11B2 gene (encoding human 11β-hydroxysteroid dehydrogenase type 2), type 1 diabetes mellitus and diabetic nephropathy. European Journal of Endocrinology 2002 146 553-558.
15. Vogt B, Dick B, N'Gankam V, Frey FJ & Frey BM. Reduced 11β-hydroxysteroid dehydrogenase activity in patients with the nephrotic syndrome. Journal of Clinical Endocrinology and Metabolism 1999 84 811-814.
16. Vierhapper H, Derfler K, Nowotny P, Hollenstein U & Waldhausl W. Impaired conversion of cortisol to cortisone in chronic renal insufficiency - a cause of hypertension or an epiphenomenon? Acta Endocrinologica 1991 125 160-164.
17. Cockcroft DW & Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 31-41.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N & Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Annals of Internal Medicine 1999 130 461-470.
19. Palermo M, Shackleton CHL, Mantero F & Stewart PM. Urinary free cortisone and the assessment of 11β-hydroxysteroid dehydrogenase activity in man. Clinical Endocrinology 1996 45 605-611.
20. Tomlinson JW, Moore JS, Clark PM, Holder G, Shakespeare L & Stewart PM. Weight loss increases 11β-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. Journal of Clinical Endocrinology and Metabolism 2004 89 2711-2716.
21. McTernan CL, Draper N, Nicholson H, Chalder SM, Driver P, Hewison M, Kilby MD & Stewart PM. Reduced placental 11β-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: An analysis of possible mechanisms. Journal of Clinical Endocrinology and Metabolism 2001 86 4979-4983.
22. Shimojo M, Ricketts ML, Petrelli MD, Moradi P, Johnson GD, Bradwell AR, Hewison M, Howie AJ & Stewart PM. Immunodetection of 11β-hydroxysteroid dehydrogenase type 2 in human mineralocorticoid target tissues: evidence for nuclear localization. Endocrinology 1997 138 1305-1311.
23. Howie AJ & Johnson GD. Confocal microscopic and other observations on the distal end of the thick limb of the human Loop of Henle. Cell Tissue Research 1992 267 11-16.
24. White JG, Amos WB & Fordham M. An evaluation of confocal versus conventional imaging of biological structures by fluorescence light microscopy. Journal of Cell Biology 1987 105 41-48.
25. Couchoud C, Pozet N, Labeeuw M & Pouteil-Noble C. Screening early renal failure: cut-off values for serum creatinine as an indicator of renal impairment. Kidney International 1999 55 1878-1884.
26. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG & Seifter JL. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Annals of Internal Medicine 1995 123 754-762.
27. Remuzzi G & Tognoni G. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano Di Studi Epidemiologici in Nefrologia). Lancet 1997 349 1857-1863.
28. Kataoka S, Kudo A, Hirano H, Kawakami H, Kawano T, Higashihara E, Tanaka H, Delarue F, Sraer JD, Mune T, Krozowski ZS & Yan K. 11β-Hydroxysteroid dehydrogenase type 2 is expressed in the human kidney glomerulus. Journal of Clinical Endocrinology and Metabolism 2002 87 877-882.
29. Shackleton CH, Rodriguez J, Arteaga E, Lopez JM & Winter JS. Congenital 11β-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: Corticosteroid metabolite profiles of four patients and their families. Clinical Endocrinology 1985 22 701-712.
30. Monder C, Shackleton CH, Bradlow HL, New MI, Stoner E, Iohan F & Lakshmi V. The syndrome of Apparent Mineralocorticoid Excess: its association with 11β-dehydrogenase and 5β-reductase deficiency and some consequences for corticosteroid metabolism. Journal of Clinical Endocrinology and Metabolism 1986 63 550-557.
31. Tomlinson JW, Draper N, Mackie J, Johnson AP, Holder G, Wood P & Stewart PM. Absence of cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. Journal of Clinical Endocrinology and Metabolism 2002 87 57-62.
32. Jamieson A, Wallace AM, Andrew R, Nunez BS, Walker BR, Fraser R, White PC & Connell JM. Apparent Cortisone Reductase Deficiency: a functional defect in 11β-hydroxysteroid dehydrogenase type 1. Journal of Clinical Endocrinology and Metabolism 1999 84 3570-3574.
33. Phillipov G, Palermo M & Shackleton CHL. Apparent Cortisone Reductase Deficiency: a unique form of hypercortisolism. Journal of Clinical Endocrinology and Metabolism 1996 81 3855-3860.
34. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, Lavery GG, Bedendo O, Ray DW, Laing I, Malunowicz E, White PC, Hewison M, Mason PJ, Connell JM, Shackleton CH & Stewart PM. Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nature Genetics 2003 34 434-439.
35. Quinkler M, Oelkers W & Diederich S. In vivo measurement of renal 11β-hydroxysteroid dehydrogenase type 2 activity. Journal of Clinical Endocrinology and Metabolism 2000 85 4921-4922.
36. Best R & Walker BR. Additional value of measurement of urinary cortisone and unconjugated cortisol metabolites in assessing the activity of 11β-hydroxysteroid dehydrogenase in vivo. Clinical Endocrinology 1997 47 231-236.
37. Whitworth JA, Stewart PM, Burt D, Atherden SM & Edwards CR. The kidney is the major site of cortisone production in man. Clinical Endocrinology 1989 31 355-361.
38. Tomlinson JW, Crabtree N, Clark PM, Holder G, Toogood AA, Shackleton CH & Stewart PM. Low-dose growth hormone inhibits 11β-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity. Journal of Clinical Endocrinology and Metabolism 2003 88 2113-2118.
39. Homma M, Tanaka A, Hino K, Takamura H, Hirano T, Oka K, Kanazawa M, Miwa T, Notoya Y, Niitsuma T & Hayashi T. Assessing systemic 11β-hydroxysteroid dehydrogenase with serum cortisone /cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure. Metabolism 2001 50 801-804.
40. Morineau G, Boudi A, Barka A, Gourmelen M, Degeilh F, Hardy N, Al-Halnak A, Soliman H, Gosling JP, Julien R, Brerault J-L, Boudou P, Aubert P, Villette J-M, Pruna A, Galons H & Fiet J. Radioimmunoassay of cortisone in serum, urine, and saliva to assess the status of the cortisol-cortisone shuttle. Clinical Chemistry 1997 43 1397-1407.
41. N'Gankam V, Uehlinger D, Dick B, Frey BM & Frey FJ. Increased cortisol metabolites and reduced activity of 11β-hydroxysteroid dehydrogenase in patients on hemodialysis. Kidney International 2002 61 1859-1866.
42. Vogt B, Dick B, Marti HP, Frey FJ & Frey BM. Reduced 11beta-hydroxysteroid dehydrogenase activity in experimental nephrotic syndrome. Nephrology Dialysis Transplantation 2002 17 753-758.
43. Kawai S, Ichikawa Y & Homma M. Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure. Journal of Clinical Endocrinology and Metabolism 1985 60 848-854.
44. Srivastava LS, Werk EE Jr, Thrasher K, Sholiton LJ, Kozera R, Nolten W & Knowles HC Jr. Plasma cortisone concentration as measured by radioimmunoassay. Journal of Clinical Endocrinology and Metabolism 1973 36 937-943.
45. Zaehner T, Plueshke V, Frey BM, Frey FJ & Ferrari P. Structural analysis of the 11β-hydroxysteroid dehydrogenase type 2 gene in end-stage renal disease. Kidney International 2000 58 1413-1419.
46. Murotsuki J, Gagnon R, Pu X & Yang K. Chronic hypoxemia selectively down-regulates 11β-hydroxysteroid dehydrogenase type 2 gene expression in the fetal sheep kidney. Biology of Reproduction 1998 58 234-239.
47. Heiniger CD, Kostadinova RM, Rochat MK, Serra A, Ferrari P, Dick B, Frey BM & Frey FJ. Hypoxia causes down-regulation of 11β-hydroxysteroid dehydrogenase type 2 by induction of Egr-1. FASEB Journal 2003 17 917-919.
48. Walker BR, Stewart PM, Shackleton CH, Padfield PL & Edwards CR. Deficient inactivation of cortisol by 11β-hydroxysteroid dehydrogenase in essential hypertension. Clinical Endocrinology 1993 39 221-227.
49. Soro A, Ingram MC, Tonolo G, Glorioso N & Fraser R. Evidence of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5β-reductase activity in subjects with untreated essential hypertension. Hypertension 1995 25 67-70.
50. Ferrari P & Krozowski Z. Role of the 11β-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. Kidney International 2000 57 1374-1381.